Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 7/14/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. William D. Kerns

Wrong Dr. William D. Kerns?

Chief Executive Officer

Phone: (978) ***-****  
Synchroneuron Inc
1000 Winter Street Suite 2000
Waltham , Massachusetts 02451
United States

Company Description: Synchroneuron was founded in 2011 by inventor and neurologist Dr. Barry Fogel, a clinical professor of psychiatry at Harvard Medical School, and the principals of...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • DVM
  • MS
  • PhD
  • D.V.M.
  • Ph.D.
94 Total References
Web References
Synchroneuron | Management Team
www.synchroneuron.com, 15 Oct 2014 [cached]
William D Kerns DVM, MS, DACVP Interim CEO
Dr. Kerns is an entrepreneur and co-founder of Synchroneuron Inc. He completed his medical training in Veterinary Medicine and graduate work in Pharmacology and Pathology at The Ohio State University. In his graduate program, he studied molecular mechanisms of cardiac hypertrophy. In 1980, he successfully completed examination by the American College of Veterinary Pathologists.
Dr. Kerns has 30 years of experience in pharmaceutical research and development, having held senior executive positions in preclinical development at SmithKlineFrench, SmithKlineBeecham, and Eisai during his pharmaceutical career. He is recognized as an expert in drug development and safety assessment and an expert on mechanisms of drug-induced cardiovascular toxicity. He has authored or co-authored over 100 articles and has co-edited a book on cardiovascular toxicology. He has been actively involved in the SOT, STP and ACVP and he has co-chaired an FDA expert committee on biomarkers of drug-induced vascular injury. .
Dr. Kerns has participated in the successful management and activation of over 200 INDs and 15 NDAs during his career. Currently he oversees the submission of 3-4 INDs each year across multiple divisions at FDA. .
Dr. Kerns is also a co-founder and the CEO of Accellient Partners, LLC, a drug development consultancy in Waltham, MA.
Synchroneuron | Board of Directors
www.synchroneuron.com, 15 Oct 2014 [cached]
William D Kerns DVM, MS Interim CEO
Dr. Kerns is an entrepreneur and co-founder of Synchroneuron Inc. He completed his medical training in Veterinary Medicine and graduate work in Pharmacology and Pathology at The Ohio State University. In his graduate program, he studied molecular mechanisms of cardiac hypertrophy. In 1980, he successfully completed examination by the American College of Veterinary Pathologists.
Dr. Kerns has 30 years of experience in pharmaceutical research and development, having held senior executive positions in preclinical development at SmithKlineFrench, SmithKlineBeecham (both now part of GlaxoSmithKline), and Eisai during his pharmaceutical career. He is recognized as an expert in drug development and safety assessment with a focus on mechanisms of drug-induced cardiovascular toxicity. He has authored or co-authored over 100 articles and has co-edited a book on cardiovascular toxicology. He has been actively involved in the SOT, STP and ACVP and he has co-chaired an FDA expert committee on biomarkers of drug-induced vascular injury. .
Dr. Kerns has participated in the successful management and activation of over 200 INDs and 15 NDAs during his career. Currently he oversees the submission of 3-4 INDs each year across multiple divisions at FDA.
Dr. Kerns is also a co-founder and the CEO of Accellient Partners, LLC, a drug development consultancy.
Scientific Advisory Board
www.sphaerapharma.com, 11 Nov 2014 [cached]
William D. Kerns, DVM, MS, DACVP Dr. William Kerns, has over 25 years of experience in Drug Discovery and Development. In addition to his role at Sphaera Pharma, he is the CEO of Accellient Partners LLC. Read more
Accellient Partners | Management Team
www.accellient.com, 4 Oct 2014 [cached]
Bill Kerns, DVM, MS, DACVP Partner Chief Executive Officer
Regulatory & Drug Development
CanFite
www.can-fite.com, 8 Mar 2012 [cached]
William D. Kerns, DVM, MS, DACVP, VP Drug Development
Dr. Kerns has over 20 years of experience in Pharmaceutical Research and Development at SmithKline Beecham and Eisai Pharmaceuticals. As a Senior Executive he has participated in the development of drugs for over 100 Phase I studies and 13 NDAs/MAAs. Bill has chaired a FDA committee on biomarkers and he is an expert in preclinical development and regulatory strategy. He is currently Managing Director, Aptuit Consulting Inc., a consulting firm with deep expertise in taking drugs from concept stage into Phase 2.
Other People with the name "Kerns":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304